Akebia Therapeutics (AKBA) Cost of Revenue (2019 - 2025)
Historic Cost of Revenue for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $9.4 million.
- Akebia Therapeutics' Cost of Revenue fell 3374.06% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.3 million, marking a year-over-year decrease of 2307.49%. This contributed to the annual value of $63.2 million for FY2024, which is 1479.72% down from last year.
- Per Akebia Therapeutics' latest filing, its Cost of Revenue stood at $9.4 million for Q3 2025, which was down 3374.06% from $9.9 million recorded in Q2 2025.
- Akebia Therapeutics' 5-year Cost of Revenue high stood at $52.5 million for Q2 2021, and its period low was -$3.4 million during Q4 2022.
- In the last 5 years, Akebia Therapeutics' Cost of Revenue had a median value of $18.0 million in 2023 and averaged $20.6 million.
- As far as peak fluctuations go, Akebia Therapeutics' Cost of Revenue plummeted by 10719.97% in 2022, and later skyrocketed by 64432.78% in 2023.
- Quarter analysis of 5 years shows Akebia Therapeutics' Cost of Revenue stood at $47.6 million in 2021, then tumbled by 107.2% to -$3.4 million in 2022, then skyrocketed by 644.33% to $18.7 million in 2023, then rose by 9.11% to $20.4 million in 2024, then plummeted by 53.93% to $9.4 million in 2025.
- Its Cost of Revenue was $9.4 million in Q3 2025, compared to $9.9 million in Q2 2025 and $7.6 million in Q1 2025.